Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Graffinity and Elan enter fragment-based discovery deal
February 2009
SHARING OPTIONS:

HEIDELBERG, GermanyŚGraffinity Pharmaceuticals GmbH announces that it has entered a research collaboration with Elan Pharmaceuticals Inc., a subsidiary of Dublin, Ireland-based Elan Corp. plc., under which Graffinity will receive technology access fees and success payments for the generation of novel small molecule hits against a number of drug targets. In turn, Elan will gain access to Graffinity's proprietary fragment-based drug discovery technology, which uses chemical microarrays and surface plasmon resonance to screen for small molecule fragments that bind to a variety of drug targets. The identification of novel modes of action and chemistry is a major focus of the collaboration. Financial details of the transaction were not disclosed. DDN


Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.